<DOC>
	<DOCNO>NCT01154140</DOCNO>
	<brief_summary>This study evaluate anti-cancer effect crizotinib compare standard chemotherapy patient ALK positive lung cancer .</brief_summary>
	<brief_title>A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Proven diagnosis locally advance suitable local treatment , recurrent metastatic nonsquamous cell carcinoma lung Positive translocation inversion event involve ALK gene locus No prior systemic treatment locally advance metastatic disease ; Patients brain metastasis treat neurologically stable ongoing requirement corticosteroid Evidence personally sign date informed consent document willingness ability comply schedule visit , treatment plan , laboratory test , study procedure include completion patient report outcome [ PRO ] measure . 18 year age old exception India upper age limit 65 year old Current treatment another therapeutic clinical trial . Prior therapy directly target ALK . Any follow within 3 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident include transient ischemic attack . Appropriate treatment anticoagulant permit . Ongoing cardiac dysrhythmias NCI CTCAE Grade &gt; =2 , uncontrolled atrial fibrillation grade , QTc interval &gt; 470 msec . Pregnancy breastfeed . Use drug food know potent CYP3A4 inducers/inhibitors Concurrent use drug CYP3A4 substrates narrow therapeutic index . Known HIV infection Known interstitial lung disease interstitial fibrosis Other severe acute chronic medical condition ( include severe gastrointestinal condition diarrhea ulcer ) psychiatric condition , laboratory abnormality would impart , judgment investigator and/or sponsor , excess risk associate study participation study drug administration , would , therefore , make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>open label</keyword>
	<keyword>randomize Phase 3</keyword>
	<keyword>first line treatment</keyword>
	<keyword>non squamous lung cancer</keyword>
	<keyword>ALK translocation event positive</keyword>
</DOC>